Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
GlobeNewswire
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024;..
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024;..
Time and time again, the community has shown that it will rally together in support of one of its own. After 17-year-old Tatum..
There has been a new medical breakthrough in the fight against myeloid leukemia or AML. A new drug for AML improves overall..